Patent · US Active

Antibody/T-cell receptor chimeric constructs and uses thereof

US11976105B2 · kind B2 · utility

0Cited by

45References

20Claims

0Family size

Assignee

Eureka Therapeutics, Inc. · US

Inventors

Jingwei Lu · Union City, US
Zhiyuan Yang · Albany, US
Cheng Liu · Richmond, US
Hong Liu · Seattle, US
Yiyang Xu · Pleasanton, US
Su Yan · Tangxia, CN
Vivien Chan · Emeryville, US
Lucas HORAN · Emeryville, US

Key dates

Filing date	Feb 22, 2021
Grant date	May 7, 2024
Priority date	—
Expiry date	Dec 31, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/74
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present application provides antibody-TCR chimeric constructs comprising an antibody moiety that specifically binds to a target antigen fused to a TCRM capable of recruiting at least one TCR-associated signaling module. Also provided are methods of making and using these constructs.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.